Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. DUOSOL WITH 4 MMOL/L POTASSIUM SOLUTION FOR HAEMOFILTRATION [SIN15785P]

DUOSOL WITH 4 MMOL/L POTASSIUM SOLUTION FOR HAEMOFILTRATION [SIN15785P]

Active ingredients: DUOSOL WITH 4 MMOL/L POTASSIUM SOLUTION FOR HAEMOFILTRATION

Last updated 26 October 2025

Product Info

DUOSOL WITH 4 MMOL/L POTASSIUM SOLUTION FOR HAEMOFILTRATION

[SIN15785P]

Product information

Active Ingredient and Strength

CALCIUM CHLORIDE DIHYDRATE (ELECTROLYTE SOLUTION) - 1.98 G/1,000 ML
GLUCOSE MONOHYDRATE (ELECTROLYTE SOLUTION) - 9.9 G/1,000 ML
MAGNESIUM CHLORIDE HEXAHYDRATE (ELECTROLYTE SOLUTION) - 0.91 G/1,000 ML
POTASSIUM CHLORIDE (ELECTROLYTE SOLUTION) - 2.68 G/1,000 ML
SODIUM CHLORIDE (ELECTROLYTE SOLUTION) - 4.21 G/1,000 ML
SODIUM CHLORIDE (SODIUM BICARBONATE SOLUTION) - 6.18 G/1,000 ML
SODIUM HYDROGEN CARBONATE (SODIUM BICARBONATE SOLUTION) - 3.59 G/1,000 ML

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

B. BRAUN AVITUM AG - GERMANY

Registration Number

SIN15785P

Licence Holder

B. BRAUN SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

B05ZB

4.1 Therapeutic indications
The ready-to-use solution is indicated for use in patients with acute renal failure requiring continuous haemofiltration.

4.2 Posology and method of administration
The use of solutions for haemofiltration in patients with acute renal failure should be under the direction of a physician with experience in using such treatment. In acute renal failure, treatment is carried out for a limited period and is discontinued when renal function is restored.

Posology

The filtration rate prescribed is dependent on the clinical status and the body weight of the patient. Unless otherwise prescribed, a filtration rate of 20–25 ml/kg body weight per hour is recommended for the removal of metabolic waste products normally excreted in the urine, depending on the metabolic condition of the patient. A maximum filtration rate of 75 litre per day is recommended.

The dose-volume is at the discretion of the physician because the volume of substitution solution depends on the intensity of treatment performed and on the amount of fluid to be replaced in order to achieve fluid balance.

Method of administration

Intravenous use.

The ready-to-use solution for haemofiltration has to be prepared by opening the peel seam. The mixing is performed by twisting the bag five times. For further instructions, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

The ready-to-use solution for haemofiltration is infused into the extracorporeal circulation by means of an infusion pump.

During haemofiltration the solution for haemofiltration replaces the ultrafiltrate removed from the blood taking into account overall fluid balance.

In acute renal failure, treatment is carried out for a limited time period and is discontinued when renal function is fully restored.

4.3 Contraindications
Specific to the ready-to-use solution for haemofiltration:

  • Hyperkalaemia

  • Metabolic alkalosis

For haemofiltration in general:

  • Acute renal failure with a marked hypercatabolic state when uraemic symptoms can no longer be corrected by haemofiltration

  • Inadequate blood flow from the vascular access

  • All states of increased risk of haemorrhage due to systemic anticoagulation